Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I have over 20 years of IT experience in the healthcare and life sciences industries, currently serving as Director of IT Business Operations at Thermo Fisher Scientific. My focus is on digital transformation, IT service delivery, and ensuring regulatory compliance through technologies like e-IFUs, cloud platforms, and cybersecurity solutions.

Q2. Are you seeing ERP systems being more tightly integrated with lab, clinical, or manufacturing systems to support end-to-end visibility? Could you please elaborate on your view on this?

Yes, ERP systems are becoming more integrated with lab, clinical, and manufacturing systems to enable real-time visibility and traceability. This supports better decision-making, faster tech transfers, and stronger compliance across the product lifecycle.

Q3. What are some key market or regulatory trends you're seeing that are influencing how IT operations need to evolve across life sciences and healthcare?

Key trends include stricter regulatory requirements like EU MDR and FDA guidelines, growing demand for data integrity and traceability, and the push for digital transformation. IT operations must now support real-time data access, cloud adoption, AI/ML integration, and tighter cybersecurity to ensure compliance, improve efficiency, and enable innovation across R&D, manufacturing, and clinical workflows.

Q4. Which market segments within life sciences and healthcare do you see experiencing the most digital disruption or growth right now—clinical trials, diagnostics, biologics, or CDMO?

Diagnostics and clinical trials are currently experiencing the most significant digital disruption. In diagnostics, AI, automation, and digital workflows are transforming how data is processed and interpreted. In clinical trials, decentralized trial models, remote monitoring, and real-time data capture are driving rapid innovation. These changes are improving speed, scalability, and patient engagement across both segments.

Q5. Are new business models (e.g., platform-based services, subscription diagnostics, lab-as-a-service) creating fresh opportunities or complexities for IT operations?

Yes, new business models, such as platform-based services, subscription diagnostics, and lab-as-a-service, are creating both opportunities and complexities. They drive innovation and new revenue streams but require IT to support scalable, secure, and compliant infrastructure. This includes flexible data integration, user access management, and robust monitoring to meet the evolving demands of both regulatory and customer requirements.

Q6. How do you see the competitive landscape evolving among life sciences and healthcare providers in terms of digital maturity and operational agility?

The competitive landscape is shifting rapidly, with digitally mature organizations gaining an edge through faster innovation, more informed data-driven decisions, and enhanced compliance. Providers investing in cloud, AI, and integrated platforms are more agile and able to respond to market changes and regulatory demands faster than traditional players. This digital maturity is becoming a key differentiator in the industry.

Q7. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

I would ask: How are you leveraging digital technologies to ensure regulatory compliance while driving innovation and operational efficiency? This reveals their balance between meeting strict industry requirements and staying competitive through technology.